Teens Are Turning to a Cancer Drug to Grow Taller. Here’s Why That’s Dangerous

Heightmaxxing is making teenagers going to some strange places.

by · ZME Science
Aedrian Salazar

A cancer drug linked to rapid growth spurts in children has caught the attention of teenagers looking to gain an extra few inches in height.

Erdafitinib, a medicine designed to treat advanced cancer, has been linked to extraordinary growth spurts in children receiving treatment for brain tumours. Reports of these effects have fuelled interest among people seeking to maximise their height – so-called “heightmaxxing”, though it’s unclear how many are actually taking the drug. However, the trend is visible enough online that TikTok has banned some accounts from promoting it.

However, the same treatment that appears to stimulate height can also interfere with normal skeletal development, potentially causing permanent damage.

Erdafitinib is a targeted cancer drug approved for treating certain patients with advanced bladder cancer. It is also used experimentally for certain types of brain tumour in children. It blocks a family of proteins called fibroblast growth factor receptors, or FGFRs.

These receptors act like molecular switches, controlling how cells grow, divide and survive. In some cancers, genetic changes leave these switches permanently on, causing cells to multiply uncontrollably. Erdafitinib interferes with these signals, slowing cancer cell growth.

Unlike conventional chemotherapy, which affects many rapidly dividing cells, targeted therapies are designed to interfere with specific molecular pathways. But these pathways are rarely exclusive to cancer.

FGFRs also work in healthy tissues, including the eyes, skin and, crucially, developing bones. Blocking them can therefore affect much more than the tumour.

The link to height lies in how bones grow. During childhood and adolescence, long bones contain regions of cartilage near their ends called growth plates. Cartilage cells in these plates multiply and enlarge before gradually being replaced by bone. This process lengthens the arms, legs and spine.

×

Get smarter every day...

Stay ahead with ZME Science and subscribe.

Daily Newsletter
The science you need to know, every weekday.

Weekly Newsletter
A week in science, all in one place. Sends every Sunday.
No spam, ever. Unsubscribe anytime. Review our Privacy Policy.

Thank you! One more thing...

Please check your inbox and confirm your subscription.

One receptor, FGFR3, helps control this process. Surprisingly, it acts as a brake rather than an accelerator on bone growth.

When FGFR3 is overactive, cartilage growth is restricted, as in achondroplasia, the most common cause of disproportionate short stature.

RelatedPosts

What country has the tallest men
New nano carrier performs both diagnosis and drug delivery to cancer cells
Cancer vaccine with 50% regression rate in mice enters clinical trial
Men’s height up 11 cm on average since the industrial age

Image credits: Ksenia Yakovleva.

Scientists have therefore investigated whether reducing FGFR3 activity might encourage bone growth. Treatments targeting this pathway are already being studied or used for certain skeletal disorders. Erdafitinib blocks several FGFR proteins, including FGFR3, raising the possibility that it could release the biological brakes on height.

But stimulating bone growth and producing a healthy, proportionate skeleton are not necessarily the same thing.

The excitement stems largely from a couple of cases. Researchers in Vienna described two children with brain tumours who experienced unexpectedly rapid growth while taking the drug. Their growth did not appear to be explained by growth hormone or puberty, which suggests the drug was directly affecting skeletal development.

An even more dramatic case involved a 15-year-old boy treated with erdafitinib for a brain tumour. Over about nine months, he grew 14.3 centimetres – far more than would be expected in that time.

However, the rapid growth came with serious skeletal abnormalities, including spinal deformities that needed corrective surgery.

These reports are scientifically important, but they involve very small numbers of seriously ill children, often receiving other treatments. They cannot tell us whether erdafitinib would safely increase the final height of healthy adolescents, or whether the extra growth would be sustained, proportionate and accompanied by normal bone strength.

Taking erdafitinib to grow taller is dangerous for several reasons. Bones, muscles, ligaments and joints must develop together to maintain strength and alignment. Accelerating one part without the others could result in deformities, abnormal spinal curvature or poor bone mineralisation.

The drug also has significant side-effects unrelated to height, including a rise in phosphate levels in the blood. Phosphate is essential for healthy bones, but excessive levels can contribute to abnormal mineral deposits in tissues. Erdafitinib can also cause serious eye problems, which may threaten vision.

In cancer medicine, such risks may be justified when a drug offers the chance of controlling a life-threatening disease. For an otherwise healthy teenager hoping to be slightly taller, the balance between benefit and harm is entirely different.

Social media discussions also tend to overlook a basic biological limit. Once puberty is complete, the growth plates normally fuse, and the long bones can no longer lengthen. There is no credible evidence that erdafitinib can make a fully grown adult taller, whatever the dose.

The high price of heightmaxxing

The popularity of heightmaxxing and other forms of maxxing reflects a broader cultural obsession with appearance, particularly among young men.

Social media increasingly presents height, muscularity and facial features as things that can, and perhaps should, be optimised. In online communities where a few extra centimetres are portrayed as the difference between romantic success and failure, the temptation to experiment with unproven treatments can be powerful.

The effects of erdafitinib on bone growth may eventually contribute to medical advances. Understanding how FGFR signalling controls skeletal development could help researchers develop treatments for children with specific growth disorders. But turning an unexpected side-effect into a safe treatment requires rigorous clinical trials, careful dosing and long-term monitoring.

For now, the lesson from erdafitinib is clear: a medicine that can make bones grow faster does not necessarily make them grow better. For anyone risking their eyesight, skeletal health and potentially permanent disability in pursuit of an extra inch or two, heightmaxxing could come at an extraordinarily high price.

Justin Stebbing, Professor of Biomedical Sciences, Anglia Ruskin University

This article is republished from The Conversation under a Creative Commons license. Read the original article.